Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 308190, 10 pages
http://dx.doi.org/10.1155/2015/308190
Research Article

Low Magnesium Levels and FGF-23 Dysregulation Predict Mitral Valve Calcification as well as Intima Media Thickness in Predialysis Diabetic Patients

1Nephrology, Hospital de Faro, Rua Leão Penedo, 8000-386 Faro, Portugal
2Fresenius Medical Care Deutschland GmbH, 61352 Bad Homburg, Germany
3Pathology Clinic, Hospital de Faro, 8000-386 Faro, Portugal
4Cardiology, Hospital de Faro, 8000-386 Faro, Portugal
5Pharmacology, Gnostic Laboratory, 8000-386 Faro, Portugal

Received 31 August 2014; Accepted 15 October 2014

Academic Editor: Ilias Migdalis

Copyright © 2015 Ana Paula Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” American Journal of Kidney Diseases, vol. 32, no. 5, pp. S112–S119, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. G. M. London, A. P. Guérin, S. J. Marchais, F. Métivier, B. Pannier, and H. Adda, “Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality,” Nephrology Dialysis Transplantation, vol. 18, no. 9, pp. 1731–1740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Noordzij, E. M. Cranenburg, L. F. Engelsman et al., “Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1662–1669, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. A. Massy and T. B. Drüeke, “Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival,” Clinical Kidney Journal, vol. 5, no. 1, pp. i52–i61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Á. L. M. de Francisco and M. Rodríguez, “Magnesium—its role in CKD,” Nefrologia, vol. 33, no. 3, pp. 389–399, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Block, P. S. Klassen, J. M. Lazarus, N. Ofsthun, E. G. Lowrie, and G. M. Chertow, “Mineral metabolism, mortality, and morbidity in maintenance hemodialysis,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2208–2218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Cozzolino, A. S. Dusso, and E. Slatopolsky, “Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure,” Journal of the American Society of Nephrology, vol. 12, no. 11, pp. 2511–2516, 2001. View at Google Scholar · View at Scopus
  8. S. K. Ganesh, A. G. Stack, N. W. Levin, T. Hulbert-Shearon, and F. K. Port, “Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients,” Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2131–2138, 2001. View at Google Scholar · View at Scopus
  9. S. Disthabanchong, “Vascular calcification in chronic kidney disease: pathogenesis and clinical implication,” World Journal of Gastroenterology, vol. 1, pp. 43–53, 2012. View at Google Scholar
  10. S. M. Moe and N. X. Chen, “Pathophysiology of vascular calcification in chronic kidney disease,” Circulation Research, vol. 95, no. 6, pp. 560–567, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Reffelmann, T. Ittermann, M. Dörr et al., “Low serum magnesium concentrations predict cardiovascular and all-cause mortality,” Atherosclerosis, vol. 219, no. 1, pp. 280–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Ishimura, S. Okuno, T. Yamakawa, M. Inaba, and Y. Nishizawa, “Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients,” Magnesium Research, vol. 20, no. 4, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Sakaguchi, N. Fujii, T. Shoji, T. Hayashi, H. Rakugi, and Y. Isaka, “Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis,” Kidney International, vol. 85, no. 1, pp. 174–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. van Laecke, E. V. Nagler, F. Verbeke, W. van Biesen, and R. Vanholder, “Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease,” The American Journal of Medicine, vol. 126, no. 9, pp. 825–831, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. T. G. M. F. Gorgels, J. H. Waarsing, A. De Wolf, J. B. Ten Brink, W. J. P. Loves, and A. A. B. Bergen, “Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum,” Journal of Molecular Medicine, vol. 88, no. 5, pp. 467–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. O. Schwille, A. Schmiedl, R. Schwille et al., “Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat—differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali,” Biomedicine and Pharmacotherapy, vol. 57, no. 2, pp. 88–97, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. F. A. R. van den Broek and A. C. Beynen, “The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice,” Laboratory Animals, vol. 32, no. 4, pp. 483–491, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Ishimura, S. Okuno, K. Kitatani et al., “Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients,” Clinical Nephrology, vol. 68, no. 4, pp. 222–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. E. Meema, D. G. Oreopoulos, and A. Rapoport, “Serum magnesium level and arterial calcification in end-stage renal disease,” Kidney International, vol. 32, no. 3, pp. 388–394, 1987. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Tzanakis, A. Pras, D. Kounali et al., “Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium,” Nephrology Dialysis Transplantation, vol. 12, no. 9, pp. 2036–2037, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Tzanakis, K. Virvidakis, A. Tsomi et al., “Intra- and extracellular magnesium levels and atheromatosis in haemodialysis patients,” Magnesium Research, vol. 17, no. 2, pp. 102–108, 2004. View at Google Scholar · View at Scopus
  22. D. M. Spiegel and B. Farmer, “Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study,” Hemodialysis International, vol. 13, no. 4, pp. 453–459, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Turgut, M. Kanbay, M. R. Metin, E. Uz, A. Akcay, and A. Covic, “Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis,” International Urology and Nephrology, vol. 40, no. 4, pp. 1075–1082, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Liu, X. Zhang, H. Qi et al., “Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients—a cross-sectional study,” Magnesium Research, vol. 26, no. 3, pp. 100–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. R. Cunha, F. Medeiros, B. Umbelino, W. Oigman, R. M. Touyz, and M. F. Neves, “Altered vascular structure and wave reflection in hypertensive women with low magnesium levels,” Journal of the American Society of Hypertension, vol. 7, no. 5, pp. 344–352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Fukagawa and J. J. Kazama, “With or without the kidney: the role of FGF23 in CKD,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1295–1298, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Russo and Y. Battaglia, “Clinical significance of FGF-23 in patients with CKD,” International Journal of Nephrology, vol. 2011, Article ID 364890, 5 pages, 2011. View at Publisher · View at Google Scholar
  28. A. Fragoso, A. P. Silva, K. Gundlach, J. Büchel, and P. L. Neves, “Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients,” Clinical Kidney Journal, vol. 7, no. 2, pp. 161–166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Gutierrez, T. Isakova, E. Rhee et al., “Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2205–2215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Publisher · View at Google Scholar
  31. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Stein, C. E. Korcarz, R. T. Hurst et al., “Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: a Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine,” Journal of the American Society of Echocardiography, vol. 21, no. 2, pp. 93–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. O. I. I. Soliman, A. M. Anwar, A. K. Metawei, J. S. McGhie, M. L. Geleijnse, and F. J. Ten Cate, “New Scores for the assessment of mitral stenosis using real-time three-dimensional echocardiography,” Current Cardiovascular Imaging Reports, vol. 4, no. 5, pp. 370–377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Nitta, “Relationship between fibroblast growth factor-23 and mineral metabolism in chronic kidney disease,” International Journal of Nephrology, vol. 2010, Article ID 167984, 7 pages, 2010. View at Publisher · View at Google Scholar
  35. N. D. Toussaint, E. Pedagogos, S.-J. Tan et al., “Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk,” Nephrology, vol. 17, no. 5, pp. 433–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. C. M. McEniery, B. J. McDonnell, A. So et al., “Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals,” Hypertension, vol. 53, no. 3, pp. 524–531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Kendrick, A. K. Cheung, J. S. Kaufman et al., “FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis,” Journal of the American Society of Nephrology, vol. 22, no. 10, pp. 1913–1922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Bernheim and S. Benchetrit, “The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases,” Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2433–2438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Corica, A. Corsonello, R. Ientile et al., “Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients,” Journal of the American College of Nutrition, vol. 25, no. 3, pp. 210–215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. M. Nasrallah, A. R. El-Shehaby, M. M. Salem, N. A. Osman, E. El Sheikh, and U. A. S. El Din, “Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2679–2685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. P.-C. T. Pham, P.-M. T. Pham, S. V. Pham, J. M. Miller, and P.-T. T. Pham, “Hypomagnesemia in patients with type 2 diabetes,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 2, pp. 366–373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Hashimoto, A. Hara, T. Ohkubo et al., “Serum magnesium, ambulatory blood pressure, and carotid artery alteration: the ohasama study,” American Journal of Hypertension, vol. 23, no. 12, pp. 1292–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Cunha, B. Umbelino, M. L. Correia, and M. F. Neves, “Magnesium and vascular changes in hypertension,” International Journal of Hypertension, vol. 2012, Article ID 754250, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. C. Montezano, D. Zimmerman, H. Yusuf et al., “Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium,” Hypertension, vol. 56, no. 3, pp. 453–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. J. J. Scialla and M. Wolf, “Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease,” Nature Reviews Nephrology, vol. 10, no. 5, pp. 268–278, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Jimbo and T. Shimosawa, “Cardiovascular risk factors and chronic kidney disease—FGF23: a key molecule in the cardiovascular disease,” International Journal of Hypertension, vol. 2014, Article ID 381082, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, and G. H. Heine, “FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment,” Nephrology Dialysis Transplantation, vol. 25, no. 12, pp. 3983–3989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Jüppner, M. Wolf, and I. B. Salusky, “FGF-23: more than a regulator of renal phosphate handling?” Journal of Bone and Mineral Research, vol. 25, no. 10, pp. 2091–2097, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Kanbay, M. I. Yilmaz, M. Apetrii et al., “Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients,” The American Journal of Nephrology, vol. 36, no. 3, pp. 228–237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Silva, A. Fragoso, C. Silva et al., “Magnesium and mortality in patients with diabetes and early chronic kidney disease,” Journal of Diabetes & Metabolism, vol. 5, article 347, 2014. View at Publisher · View at Google Scholar